| Major Depressive Disorder
Caplyta vs Zoloft
Side-by-side clinical, coverage, and cost comparison for major depressive disorder.Deep comparison between: Caplyta vs Zoloft with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoloft has a higher rate of injection site reactions vs Caplyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoloft but not Caplyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caplyta
Zoloft
At A Glance
Oral
Once daily
Atypical antipsychotic
Oral
Daily
SSRI
Indications
- Schizophrenia
- Depression, Bipolar
- Major Depressive Disorder
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Panic Disorder
- Post-Traumatic Stress Disorder
- Phobia, Social
- Premenstrual Dysphoric Disorder
Dosing
Schizophrenia, Depression, Bipolar, Major Depressive Disorder 42 mg orally once daily with or without food; no dose titration needed.
With strong CYP3A4 inhibitors Reduce to 10.5 mg once daily.
With moderate CYP3A4 inhibitors Reduce to 21 mg once daily.
Moderate or severe hepatic impairment Reduce to 21 mg once daily (Child-Pugh class B or C).
Major Depressive Disorder Starting 50 mg/day orally; max 200 mg/day; titrate by 25-50 mg/day increments once weekly if inadequate response.
Obsessive-Compulsive Disorder Starting 25 mg/day (ages 6-12) or 50 mg/day (ages >=13) orally; max 200 mg/day; titrate by 25-50 mg/day increments once weekly if inadequate response.
Panic Disorder, Post-Traumatic Stress Disorder, Phobia, Social Starting 25 mg/day orally; max 200 mg/day; titrate by 25-50 mg/day increments once weekly if inadequate response.
Premenstrual Dysphoric Disorder Continuous dosing: starting 50 mg/day orally, max 150 mg/day; intermittent (luteal phase only): starting 50 mg/day, max 100 mg/day.
Contraindications
- History of hypersensitivity reaction to lumateperone or any component of CAPLYTA (including pruritus, rash, and urticaria)
- Concomitant use or use within 14 days of stopping MAOIs, including linezolid and intravenous methylene blue, due to increased risk of serotonin syndrome
- Concomitant use of pimozide
- Known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema)
- Concomitant use of disulfiram with ZOLOFT oral solution (contains alcohol)
Adverse Reactions
Most common (>=5%) Somnolence/sedation, dizziness, nausea, dry mouth, headache, fatigue, diarrhea, vomiting
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension and syncope, seizures, suicidal thoughts and behaviors, cerebrovascular adverse reactions including stroke in elderly patients with dementia-related psychosis
Postmarketing Burning sensation, including skin burning sensation
Most common (>=5%) Nausea, diarrhea/loose stools, tremor, dyspepsia, decreased appetite, hyperhidrosis, ejaculation failure, decreased libido
Serious Suicidal thoughts and behaviors, serotonin syndrome, QTc prolongation and ventricular arrhythmias, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, hyponatremia, sexual dysfunction
Postmarketing Agranulocytosis, aplastic anemia, Stevens-Johnson Syndrome, toxic epidermal necrolysis, severe liver events including hepatitis and liver failure, QTc-interval prolongation, ventricular tachycardia, extrapyramidal symptoms, pulmonary hypertension, cerebrovascular spasm
Pharmacology
Lumateperone is an atypical antipsychotic whose mechanism may be mediated through antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors; it also has moderate SERT inhibitory activity and moderate binding affinity for dopamine D1, D4, and adrenergic alpha-1 receptors.
Sertraline is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT), with only very weak effects on norepinephrine and dopamine reuptake and no significant affinity for adrenergic, cholinergic, GABA, dopaminergic, or histaminergic receptors; it does not inhibit monoamine oxidase.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caplyta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (2/12)
Zoloft
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (3/12)
UnitedHealthcare
Caplyta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Zoloft
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Caplyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoloft
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Schizophrenia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Zoloft.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaplytaView full Caplyta profile
ZoloftView full Zoloft profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.